GICS Sector : Healthcare
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia.It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery.The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Asensus Surgical Announces Closing of Acquisition by KARL STORZ
Aug -22
Asensus Surgical, Inc. (ASXC) Q2 2024 Earnings Call Transcript
Aug -13
Asensus Surgical, Inc. Schedules Second Quarter Financial and Operating Results Conference Call for August 13, 2024
Aug -08
Asensus Surgical 2024 Special Meeting of Stockholders Is Adjourned
Aug -07
Independent Proxy Advisory Firm ISS Recommends Asensus Surgical Stockholders Vote “FOR” the Pending Merger with KARL STORZ
Jul -30
Glass Lewis Recommends Asensus Surgical Stockholders Vote “FOR” Proposals Relating to Proposed Merger with KARL STORZ
Jul -29
Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in Urology
Jul -23
Asensus Surgical Announces LKH-Universitätsklinikum Graz Hospital in Austria to Initiate Senhance Surgery Program
Jul -16
Asensus Surgical's 9.9% growth is driven by increasing adoption of its Senhance Surgical System, a digital laparoscopic platform, in the laparoscopic and robotic-assisted surgery markets. Growing demand for minimally invasive procedures, expansion into new geographies, and strategic partnerships are also contributing to the company's growth.
Asensus Surgical, Inc.'s leases growth of 8.22% is driven by increasing adoption of robotic-assisted surgery, expansion into new markets, and strategic partnerships. Growing demand for minimally invasive procedures, advancements in surgical robotics, and favorable reimbursement trends also contribute to this growth.
Asensus Surgical, Inc.'s Instruments and Accessories segment growth of 8.5% is driven by increasing adoption of robotic-assisted surgery, growing demand for minimally invasive procedures, and expansion into new geographic markets. Additionally, the company's focus on innovation, product development, and strategic partnerships are contributing to the segment's growth.
Asensus Surgical, Inc.'s 9.98% growth is driven by increasing adoption of robotic-assisted surgery, growing demand for minimally invasive procedures, and expansion into new markets. Additionally, the company's Senhance Surgical System's unique features, such as haptic feedback and 3D visualization, are attracting more surgeons and hospitals, contributing to the growth.
A digital laparoscopic platform that enables surgeons to perform a wide range of procedures, including general surgery, gynecologic surgery, and urologic surgery.
A line of articulating, high-dexterity instruments designed to work seamlessly with the Senhance Surgical System.
A high-definition, 3D visualization system that provides surgeons with a detailed, immersive view of the surgical site.
A machine learning-based technology that enables real-time analysis of surgical video and provides surgeons with actionable insights to improve surgical technique.
Asensus Surgical, Inc. faces moderate threat from substitutes, as there are limited alternative products or services that can replace its surgical robotic systems.
Asensus Surgical, Inc. has a diverse customer base, which reduces the bargaining power of individual customers, and the company's products are often critical to its customers' operations, making it difficult for them to switch suppliers.
Asensus Surgical, Inc. relies on a few key suppliers for critical components, which gives them some bargaining power, but the company's size and scale also give it some negotiating power.
The medical device industry has high barriers to entry, including significant regulatory hurdles and the need for substantial investment in research and development, which limits the threat of new entrants.
The medical device industry is highly competitive, with several established players competing for market share, and Asensus Surgical, Inc. faces intense competition from companies such as Intuitive Surgical and Medtronic.
| Value | |
|---|---|
| Debt Weight | 14.53% |
| Debt Cost | 3.95% |
| Equity Weight | 85.47% |
| Equity Cost | 11.10% |
| WACC | 10.06% |
| Leverage | 17.00% |
Value: 9.0
Growth: 3.2
Quality: 5.6
Yield: 0.0
Momentum: 10.0
Volatility: 0.7
1-Year Total Return ->
Value: 6.0
Growth: 6.0
Quality: 4.3
Yield: 0.0
Momentum: 10.0
Volatility: 0.7
1-Year Total Return ->
Value: 6.0
Growth: 3.9
Quality: 2.2
Yield: 0.0
Momentum: 8.0
Volatility: 2.0
1-Year Total Return ->
Value: 8.0
Growth: 4.4
Quality: 3.6
Yield: 0.0
Momentum: 5.0
Volatility: 0.7
1-Year Total Return ->
Value: 5.4
Growth: 7.7
Quality: 6.0
Yield: 0.0
Momentum: 0.0
Volatility: 1.0
1-Year Total Return ->
Value: 8.0
Growth: 2.1
Quality: 3.4
Yield: 0.0
Momentum: 1.0
Volatility: 0.3
1-Year Total Return ->